Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.
KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously
Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial
Marketing potential Pipeline candidates address large, multi-billion dollar markets
Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.
Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.
MicroCap Alert to CHFS shareholders. Why Clean Energy Technologies (CETY) shares moved up recently and why they are about to rise sharply again. CETY purchased their Heat Recovery Systems from General Electric. Each system sells for about $300,000. Demand for CETY HRS is very strong. CETY just expanded Europe sales and service office in high demand market CETY immediately announced first new sale in Europe CETY presenting to 26 Power Companies in the Pacific on July 31st to August 4th – These 26 power companies need CETY HRS to produce power cheaper and make more profits.
Expect substantial sales orders to flow soon after conference CETY 1017 target: $.15 to $.20
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.7 In other words, the correlation coefficient of the other stock
We need volume to rise.
closer to .80 than .60
$CHFS UPON PR.WERE GIBBS SKYROCKET TARGET PRICE $6.00 BIO CURES CONGESTIVE HEART FAILURE RATED A STRONG BUY AND HOLD$$$$$
This is going to run on PR NEWS Merger with Major drug company and FDA APPROVAL RATED A STRONG BUY AND HOLD=$$$$$
Never fails. There are always fools selling at the bottom and parting with their money. This is where you should be buying. I have finished buying 80K shares with average of .79. May take another several months to pop again but this is easy money. Float is simply too low. Stupid to set stop losses at these levels but MM will always take them out. Downside risk from here, less than 15%. Upside potential, +100%-200% again. Board will once again get quite as volume dies up and losers lick those wounds and move on.
Buy more for Monday, will have a nice close today
Anyone know a brokerage that will let me short a 60 cent stock?
This will be back over a dollar soon.
Trader Check $ BONT
CHF Solutions Retains Laurent Duhoux as International Business Development Consultant to Expand International Markets for Aquadex Flexflow(R) System Font size: A | A | A 8:00 AM ET 7/11/17 | GlobeNewswire
CHF Solutions, Inc. (NASDAQ:CHFS) announced today that Laurent Duhoux joined the Company as International Business Development consultant. In this capacity, Mr. Duhoux will be responsible for European and Asian market expansion for the Aquadex FlexFlow system.
"I am very excited to welcome Laurent to CHF Solutions. His deep experience and proven track record of success is opportune at this exciting time in our evolving future, as we continue to grow our ultrafiltration business," said John Erb, Chairman and Chief Executive Officer of CHF Solutions. "Laurent brings 25 years of proven marketing leadership and medical device expertise in international product launches, marketing program management, KOL development and developing health economic strategies and will be invaluable as we re-launch our product internationally."
Prior to his engagement with CHF Solutions, Mr. Duhoux spent 7 years with Edwards Life Sciences in several senior marketing positions, launching new products and building the European market for those products. Prior to his Edwards experience, Mr. Duhoux spent 18 years with Gambro Renal Products, with the last four years as Vice President of the Intensive Care Business. Mr. Duhoux was the senior marketing executive and championed the analysis and recommendation leading to Gambro's decision in 2010 to acquire the company that originally developed the Aquadex FlexFlow system. Mr. Duhoux is fluent in English, French, German, Spanish and Portuguese. He holds a Master Degree in Biomedical Engineering from the University of Lyon, Franc
I hate selling for a loss, any chance this turns around? Hard to watch this go down further and further each day. Had the chance to sell yesterday and the day before at a little over $1 for a minimal loss and didn't take it. Wondering if we'll see $1 again in the near future.